Hypofractionated radiation therapy for treatment of bladder carcinoma in patients aged 90 years and more: A new paradigm to be explored?
Méry B1,
Falk AT,
Assouline A,
Trone JC,
Guy JB,
Rivoirard R,
Auberdiac P,
Escure JL,
Moncharmont C,
Moriceau G,
Almokhles H,
de Laroche G,
Pacaut C,
Guillot A,
Chargari C,
Magné N.
Abstract
INTRODUCTION:
There are only scarce data on the optimal management of patients who present with a bladder carcinoma and who are aged 90 years and older.
PATIENTS AND METHODS:
We retrospectively reviewed records from radiotherapy departments from two university hospitals, two private centers and one public center to identify patients who underwent radiotherapy for bladder cancer over the past decade and who were aged 90 years or older. From 2003 to 2013, 14 patients aged 90 years or older receiving RT for bladder malignant tumors were identified.
RESULTS:
Mean age was 92.7 years. Ten patients (71 %) had a general health status altered (PS 2-3) at the beginning of RT. A total of 14 RT courses were delivered, including six treatments (43 %) with curative intent and eight treatments (57 %) with palliative intent. Palliative intent mainly encompassed hemostatic RT (36 %). At last follow-up, two patients (14 %) experienced complete response, one patient (7 %) experienced partial response, three patients (21 %) had their disease stable, and three patients (21 %) experienced tumor progression, of whom two patients with the progression of symptoms. There was no reported high-grade acute local toxicity in 14 patients (100 %). One patient experienced delayed grade 2 toxicity with pain and lower urinary tract symptoms. At last follow-up, seven patients (50 %) were deceased. Cancer was the cause of death for five patients.
CONCLUSION:
Hypofractionated radiotherapy remains feasible for nonagenarians with bladder cancer. Further investigations including analysis of geriatric comorbidities and impact of treatments on quality of life should be conducted.
- PMID:
- 25982585
- [PubMed - as supplied by publisher]
No comments:
Post a Comment